logo-loader
Redx Pharma Plc

Redx Pharma chief "encouraged" by latest data on fibrosis drug candidate

Redx Pharma Plc’s (LON:REDX) chief executive Lisa Anson tells Proactive London how “encouraged” she and the company is about the latest pre-clinical data from a fibrosis drug set to enter human trials next year.News here too on what this means for the company and indeed fibrosis sufferers themselves.The lab tests showed the Redx drug was able to suppress collagen deposition and pathways associated with fibrosis, meaning it could have an impact on established forms of the disease.
Its profile suggests the putative treatment is suitable to be taken by mouth, rather than injected directly into the blood system.
Three independent studies assessed the potential efficacy of the company’s lead ROCK2 compound in animal models of lung, kidney and liver fibrosis.

Quick facts: Redx Pharma Plc

Price: £0.09

Market: AIM
Market Cap: £11.1 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New Redx CEO bringing leadership and skills to 'capitalise on its great science'

Lisa Anson, the new chief executive at Redx Pharma Plc (LON:REDX), sat down with Proactive's Andrew Scott just weeks after taking on the new role. Anson was the president of AstraZeneca PLC’s (LON:AZN) UK division immediately prior to joining, while she's also held various other senior...

on 19/7/18

2 min read